Synterica

Synterica

Biotechnology, 2924 Guilford Ave, Baltimore, Maryland, 21218, United States, 1-10 Employees

synterica.com

  • LinkedIn

Who is SYNTERICA

Synterica makes oral therapeutics for treatment of enteric disease with a goal of promoting gastrointestinal health. Our products directly target pathogenic bacteria and their toxins in t...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 8111

checked-icon Does something look wrong? Fix it. | View contact records from SYNTERICA

Synterica Org Chart and Mapping

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Synterica

Answer: Synterica's headquarters are located at 2924 Guilford Ave, Baltimore, Maryland, 21218, United States

Answer: Synterica's official website is https://synterica.com

Answer: Synterica's revenue is Under $1 Million

Answer: Synterica's SIC: 8111

Answer: Synterica has 1-10 employees

Answer: Synterica is in Biotechnology

Answer: Synterica contact info: Phone number: Website: https://synterica.com

Answer: Synterica makes oral therapeutics for treatment of enteric disease with a goal of promoting gastrointestinal health. Our products directly target pathogenic bacteria and their toxins in the gut without harming beneficial bacteria. While antibiotics have saved many lives, we live in an era when bacterial resistance to antibiotics has become a problem. In addition to the problems of resistance, antibiotics can disrupt the healthy balance of gut microflora allowing pathogenic bacteria to flourish and directly contribute to disease. These problems drive the need for new and innovative therapeutics. Synterica is developing innovative therapeutics that directly bind to and eliminate selected pathogenic bacteria and their toxins in the gut. We do this by combining specific targeting and neutralizing agents with natural packaging material made from living ingestible organisms that also serve as the means for large-scale production. Our first target is an oral therapeutic to neutralize the toxins secreted by Clostridium difficile. The two toxins are responsible for the devastating effects of the infection and neutralizing them is expected to reduce pathogenesis of the disease.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access